TWP
VVOS icon

Triad Wealth Partners’s Vivos Therapeutics VVOS Stock Holding History

Triad Wealth Partners’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,818
Closed -$6.26K – 923
2024
Q2 		$6.26K Buy
+2,818
New +$6.87K ﹤0.01% 520

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Triad Wealth Partners's VVOS Position: Q3 2024 in Review

Triad Wealth Partners sold out of Vivos Therapeutics (VVOS) in Q3 2024, closing a stake of 2,818 shares — an estimated $6.26K sold.

Triad Wealth Partners first reported a position in VVOS in Q2 2024 and held it in 1 quarter. The position peaked at $6.26K in Q2 2024. 23 funds tracked by Wall St. Rank hold VVOS as of Q3 2024.

  • Triad Wealth Partners reported no remaining Vivos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Triad Wealth Partners sold 2,818 Vivos Therapeutics shares in Q3 2024, an estimated $6.26K.
  • Triad Wealth Partners first reported a position in Vivos Therapeutics in Q2 2024 and held it in 1 quarter.
  • Triad Wealth Partners's Vivos Therapeutics position peaked at $6.26K in Q2 2024.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q3 2024.

Based on Triad Wealth Partners's 13F filing for Q3 2024, filed 21 Oct 2024.